1. Gene Therapy with Fidanacogene Elaparvovec in Adults with Hemophilia B.
- Author
-
Cuker, A., Kavakli, K., Frenzel, L., Wang, J.-D., Astermark, J., Cerqueira, M. H., Iorio, A., Katsarou-Fasouli, O., Klamroth, R., Shapiro, A. D., Hermans, C., Ishiguro, A., Leavitt, A. D., Oldenburg, J. B., Ozelo, M. C., Teitel, J., Biondo, F., Fang, A., Fuiman, J., and McKay, J.
- Subjects
- *
BLOOD coagulation factor IX , *ADENO-associated virus , *GENE therapy , *HEMOPHILIA treatment , *BODY weight - Abstract
BACKGROUND: Fidanacogene elaparvovec, an adeno-associated virus (AAV) gene-therapy vector for hemophilia B containing a high-activity human factor IX variant (FIX-R338L/FIX-Padua), was associated with sustained factor IX activity in a phase 1-2a study. METHODS: We conducted a phase 3 open-label study of fidanacogene elaparvovec at a dose 5><1011 vector genome copies per kilogram of body weight. Men 18 to 65 years of age with hernophilia B and a factor IX level of 296 or less were eligible for screening they had received at least 6 months of therapy with prophylactic factor IX concentrate. The primary end point, tested for noninferiority, was the annualized bleeding rate (treated and untreated bleeding episodes) from week 12 to month 15 after treatment with fidanacogene elaparvovec as compared with the prophylaxis lead-period. Superiority, additional efficacy end points, and safety were also assessed. RESULTS: Of 316 men who underwent screening for the lead-in study, 204 (64.6%) were not eligible; 188 (59.5°/o) of those were ineligible owing to the presence of anti-AAV neutralizing antibodies. Of the 45 participants who received fidanacogene elaparvovec, 44 completed at least 15 months of follow-up. The annualized rate of bleeding for all bleeding episodes decreased by 71°/0, from 4.42 (95% confidence interval [CI], 1.80 to 7.05) at baseline to 1.28 (95% CI, 0.57 to 1.98) after gene therapy, treatment difference of-3.15 episodes (95% CI, -5.46 to -0.83; P=0.008). This result shows the noninferiority and superiority of fidanacogene elaparvovec prophylaxis. At 15 months, the mean factor 1X activity was 26.9°/0 (median, 22.990; range, 1.9 to 119.0) by one-stage SynthASil assay. A total of 28 participants (62°/received glucocorticoids for increased aminotransferase levels or decreased factor IX levels (or both) starting between 11 and 123 days. No infusion-related serious adverse events, thrombotic events, development of factor IX inhibitors, or malignant conditions were observed. CONCLUSIONS: Fidanacogene elaparvovec was superior to prophylaxis for the treatment of participants with hemophilia B, leading to reduced bleeding and stable factor IX expression. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF